Neurology
Baylor joins Parkinson's Progression Markers Initiative as official site
September 28, 2010 8:32 am | by Baylor College of Medicine | News | CommentsThe Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine is an official site for the Parkinson's Progression Markers Initiative, sponsored by The Michael J. Fox Foundation for Parkinson's Research. Enrollment at Baylor has begun and will continue for...
Mapping the Brain on a Massive Scale
September 27, 2010 9:31 pm | by Massachusetts Institute of Technology | News | CommentsScanning 1,200 brains could help researchers chart the organ's fine structure and better understand neurological disorders.
Valeant and Biovail Announce Results of Special Meetings of Shareholders
September 27, 2010 1:32 pm | by Bio-Medicine.Org | News | CommentsALISO VIEJO, Calif. and TORONTO, Sept. 27 /- Valeant Pharmaceuticals International (NYSE: VRX ) and Biovail Corporation (NYSE/TSX: BVF) announced that at today's Special Meetings, each of which had a quorum of shareholders, shareholders of both companies have voted overwhelmingly in...
InVivo Therapeutics names Moran as new CFO
September 27, 2010 10:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsInVivo Therapeutics Corp., a Cambridge biotech working on implants for spinal cord injuries, has appointed a new chief financial officer in Sean Moran, co-founder and former CFO of Anika Therapeutics Inc.
Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
September 23, 2010 12:31 pm | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept, 23 /- Reportlinker.com announces that a new market research report is available in its catalogue: Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets...
Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets
September 23, 2010 9:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Sept. 23 /- Reportlinker.com announces that a new market research report is available in its catalogue: Spinal Surgical Devices: Technologies and Global Markets http://www.reportlinker.com/p0297996/Spinal-Surgical-Devices-Technologie... THIS REPORT CONTAINS...
NSF grant aids Boston-area high schools in biology curriculum
September 20, 2010 10:31 am | by Mass High Tech: The Journal of New England Technology | News | CommentsThe National Science Foundation has awarded a $2.2 million grant to MIT associate professor Eric Klopfer and UPenn assistant professor Susan Yoon for the creation of a high school biology curriculum that includes the teaching of complex systems.
Questcor to Present at UBS Global Life Sciences Conference
September 20, 2010 4:33 am | by Bio-Medicine.Org | News | CommentsUNION CITY, Calif., Sept. 20 /- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR ) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will...
Lantos Technologies raises $1.6M in Series A round
September 16, 2010 5:31 am | by Mass High Tech: The Journal of New England Technology | News | CommentsLantos Technologies Inc., a health-focused 3-D scanning technology startup, has raised the expected $1.6 million in it Series A round of funding. Leading the round was Catalyst Health Ventures of Braintree.
A Drug Shows Promise in Autism
September 14, 2010 9:35 pm | by Massachusetts Institute of Technology | News | CommentsA chemical that alters chemical signaling seems to ease anxiety and other symptoms.
Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
September 14, 2010 5:36 pm | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Sept. 14 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive...
Wheelchair Makes the Most of Brain Control
September 12, 2010 8:32 pm | by Massachusetts Institute of Technology | News | CommentsArtificial intelligence improves a wheelchair system that could give paralyzed people greater mobility.
Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
September 10, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Sept. 10 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Rodman & Renshaw Annual Global Investment Conference. The details are as...
Mapping How the Brain Matures
September 9, 2010 9:32 pm | by Massachusetts Institute of Technology | News | CommentsNew analysis tools may eventually help doctors predict autism and other developmental disorders.
Elekta Among Major Sponsors of Rocks Against Cancer Fundraiser
September 8, 2010 7:32 am | by Bio-Medicine.Org | News | CommentsATLANTA, Sept. 8 /- Elekta is one of the leading supporters of the Rocks Against Cancer benefit to take place September 16 at the Angel Orensanz Foundation for the Arts in New York City. Proceeds from the event will support EIF cancer programs, including Stand Up to Cancer (SU2C), an...
James F. Szigethy Named Curemark's Director of New Product Development
September 7, 2010 8:36 am | by Bio-Medicine.Org | News | CommentsRYE, N.Y., Sept. 7 /- Curemark ( www.curemark.com ), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development. In...
MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
September 7, 2010 6:35 am | by Bio-Medicine.Org | News | CommentsMOUNTAIN VIEW, Calif., Sept. 7 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the Company will participate in the following healthcare conferences in September: Morgan Stanley Global Healthcare Conference Tuesday, September 14, at 11:30 a.m. ET in New York Stifel...
Pfizer ends deal with Celldex
September 3, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsCelldex Therapeutics Inc. has said Pfizer Vaccines LLC terminated its agreement with the Needham-based biotechnology firm to develop a potential brain cancer vaccine.
Results From Investigator-Sponsored Trials Presented at SSIEM Conference
September 1, 2010 7:31 am | by Bio-Medicine.Org | News | CommentsNOVATO, Calif., Sept. 1 /- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society for The Study of Inborn Errors of Metabolism...
Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
August 31, 2010 10:32 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue: Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016...
Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
August 31, 2010 4:35 am | by Bio-Medicine.Org | News | CommentsWALTHAM, Mass., Aug. 31 /- Repligen Corporation (Nasdaq: RGEN ) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 13th, 2010 at 12:05 p.m. EDT...
GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
August 30, 2010 7:32 pm | by Bio-Medicine.Org | News | CommentsLONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /- GlaxoSmithKline (NYSE: GSK ) and Valeant Pharmaceuticals International (NYSE: VRX ) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for...
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 27, 2010 6:34 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Aug. 27 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options...
BCM pediatric cancer researchers get funding from St. Baldrick's Foundation
August 26, 2010 1:32 pm | by Baylor College of Medicine | News | CommentsThree Baylor College of Medicine physician-scientists have received support totaling more than $500,000 from St. Baldrick's Foundation to advance their research in pediatric cancer. Dr. Karen Rabin, assistant professor of pediatrics – hematology/oncology, was named a St. Baldrick's...
Brain imaging gives new insight into mental disorders
August 25, 2010 9:36 am | by Baylor College of Medicine | News | CommentsA new kind of psychiatry built on objective measures derived from functional magnetic resonance imaging (or fMRI) of the brain performed while patients play economic games could provide new insight into the diagnosis and, eventually, treatment of mental disorders, said researchers from...
